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Background: Breast cancer is the most common cancer amongst Malaysian women. Both the disease and its
treatment can disrupt the lives of the woman and adversely affect all aspects of life and thus can alter a woman’s
quality of life. The aim of this study was to examine the effect of virgin coconut oil (VCO) on the quality of life
(QOL) of patients diagnosed with breast cancer.
Methods: This was a prospective study of breast cancer patients admitted into the Oncology Unit of Hospital
Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. The sample consisted of 60 patients with stage III and IV
breast cancer allocated to either an intervention group (n = 30) or a control group (n = 30) using a simple random
table. QOL was evaluated from the first cycle of chemotherapy to the sixth cycle, and data were collected using a
validated Bahasa Malaysia version of the European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire Breast Cancer Module (EORTC QLQ-C30) and its breast-specific module (QLQ-BR 23).
Results: The mean age of breast cancer patients was 50.2 (SD = 13.5) years. There were significant mean score
differences for functioning and global QOL between groups (α < 0.01). The intervention group also had better
scores for symptoms including fatigue, dyspnea, sleep difficulties, and loss of appetite compared to the control
group. Although there are deteriorations for sexual enjoyment, the intervention group exhibited improvement in
breast functioning and symptom scores for body image, sexual function, future perspective, breast symptoms,
and systemic therapy side effects.
Conclusion: VCO consumption during chemotherapy helped improve the functional status and global QOL of
breast cancer patients. In addition, it reduced the symptoms related to side effects of chemotherapy.
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In Malaysia, breast cancer is the most common cancer
that affects women and rated as the main cause of mor-
tality, among other cancers [1]. According to the third
report of the National Cancer Registry (2003–2005), the
incidence of breast cancer among women in Malaysia is
31.3%. The high mortality rate of breast cancer also con-
tributed to the 15.2% of medically certified death due to
cancer [2].* Correspondence: lawks@amdi.usm.edu.my
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unless otherwise stated.Chemotherapy and radiotherapy are commonly used
after primary treatment of breast cancer to inhibit metas-
tasis and enhance long-term survival rates [3-6]. However
chemotherapy often is associated with many negative side
effects such as nausea and vomiting, hair loss, fatigue,
pain, anxiety, depression and others [7-9]. Most of the side
effects were perceived by the patients as distressing and
many were anxious during the treatment. Both the disease
and its treatment can disrupt the lives of the woman and
adversely affect all aspects of life and thus can alter a
woman’s quality of life (QOL) [7,10-15]. Akin et al., [16]
demonstrated that the adverse effects of different cancer
or treatment-related symptoms and types of treatment. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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health-related QOL may affect daily life in patients with
breast cancer [17].
Virgin coconut oil (VCO) is a traditional product that
has a long history of ethnopharmacological use. VCO is
extracted from fresh coconut flesh at low temperature
and without the use of chemicals. Studies have shown
that coconut oil inhibits the induction of carcinogenic
agents in the colon and in mammary tumours in test
animals [18-20]. In chemically induced cancers of the
colon and breast, coconut oil was shown to be more
protective than unsaturated oil. Coconut oil which is rich
in medium chain fatty acids, and ideal for immune sup-
pressed individuals. For this reason, it is being studied as
a treatment for HIV/AIDS patients whose immune
systems are severely compromised [21]. In a clinical study
conducted by Soerjodibroto [22] of the effects of VCO
on immune responses among HIV positive patients, he
concluded that the macronutrient intake, mostly in terms
of energy, fats and protein were significantly improved
among the VCO supplemented group compared to the
control group. In addition, the weight and nutritional status
of the subjects, especially among the VCO-supplemented
group, were maintained well throughout the study.
To date, studies on the use of VCO as a dietary sup-
plement in the treatment of cancer patients to improve
their QOL are limited. However, this information could
help healthcare professionals care for cancer patients
and help them maintain a good QOL during treatment.
Thus, the purpose of this study was to empirically evalu-
ate the effect of VCO supplementation on the QOL of
breast cancer patients undergoing chemotherapy in Ke-
lantan, Malaysia.
Methods
Study design
This was a prospective study of health-related QOL of
breast cancer patients. The study was conducted in the
Hospital Universiti Sains Malaysia (HUSM) located in
Kelantan, Malaysia. HUSM is a tertiary and teaching hos-
pital in Malaysia. The sixty participants included in this
study were women ≥ 18 years old who were diagnosed
with stage III or IV breast cancer and who underwent six
cycles of first-line chemotherapy.
Pre-assessment using the study instrument was con-
ducted among patients who met the study inclusion criteria
during their first visit for their first cycle of chemotherapy.
During their second cycle of chemotherapy, patients were
randomly assigned to either the intervention or control
group using a simple random sampling. Patients in the
intervention group (n = 30) were given VCO (10 ml twice
daily) as a supplement after 1 week each chemotherapy
cycle from the third until the sixth cycle, whereas patients
in the control group did not receive any supplement.Ethical approval for the study was obtained from the
Human Research Ethics Committee, USM and the Director
of HUSM. The patients were informed about the study and
the informed consent was obtained from the patients.
Outcome measures
QOL was measured using the translated Bahasa Malaysia
version of the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire–Core
30 (EORTC QLQ-C30) and the Breast Cancer Supple-
mentary Measure (QLQ-BR23) questionnaire. The psy-
chometric properties of the translated version for both
questionnaires have been well documented [23,24].
The EORTC QLQ-C30 is a well-known instrument for
measuring QOL in cancer patients. It contains 30 items
that measure the following three main domains: global
health status, functional status, and cancer-related symp-
tom status. The QLQ-BR23 is a breast cancer-specific set
of 23 questions for assessing functional status and symp-
toms related to breast cancer. The EORTC raw score of a
participant’s responses is transformed according to the
EORTC scoring manual [25] into a score ranging from 0
to 100, with a higher score indicating better QOL for
functioning and global QOL. For cancer-specific symp-
toms, a higher score indicates more or worse symptoms
and thus a poorer QOL.
Socio-demographic data collected in this study include
age, ethnicity, education level, occupation, household in-
come, marital status, number of children, breastfeeding his-
tory, and family history. Clinical data consisting of disease
stage and comorbidity were extracted from the participants’
medical records. The patients were interviewed at five time
points (first, third, fourth, fifth, and sixth visits) during the
six-course therapy cycle. Data were collected personally via
interview by the researcher. Time to complete the ques-
tionnaire was approximately 15–20 minutes.
Analysis
Data were analyzed using the Statistical Package for Social
Sciences (SPSS) version 18. Descriptive statistics were
used to summarize the patients’ sociodemographic data,
and differences between the characteristics of the inter-
vention and control groups were evaluated using the chi
square test. The effect of VCO consumption on QOL was
determined by calculating the mean score difference be-
tween the intervention and control groups. An independ-
ent t-test was used to compare the QOL domains score
between the intervention and control groups. P ≤ 0.01 was
considered to be statistically significant.
Results
Characteristics of the study group
A total of 68 women who were diagnosed with stage III or
IV breast cancer were asked to participate in this study.
Table 1 Sociodemographic data and clinical
characteristics of the study sample (n = 60)
Variables Frequency (%) P*
Intervention group
(n = 30)
Control group
(n = 30)
Age group (years) 0.386
< 40 6 (19.4) 9 (29.3)
40–50 14 (48.3) 9 (29.3)
> 50 10 (32.3) 12 (41.4)
Mean (SD) 47.10 ( 8.2) 49.90 (11.5)
Range 31–73 30–64
Race 0.097
Malays 29 (96.7) 24 (80.0)
Chinese 1 (3.3) 4 (13.3)
Indian – 2 ( 6.7)
Educational level 0.131
None – 3 (10.0)
Primary 4 (13.3) 7 (23.3)
Secondary 16 (53.3) 11 (36.7)
College/University 10 (33.3) 9 (30.0)
Occupation 0.694
Housewife 14 (46.7) 12 (40.0)
Civil servant 13 (43.3) 14 (46.7)
Private sector 3 (10.0) 4 (13.3)
Income 0.209
< RM 1000 3 (10.0) 9 (30.0)
RM 1000-RM3000 17 (56.7) 10 (33.3)
>RM3000 10 (33.3) 11 (36.7)
Marital status 0.385
Single 1 (3.3) 1 (3.3)
Married 27 (90.0) 25 (83.3)
Divorced 1 (3.3) –
Widowed 1 (3.3) 4 (13.3)
Number of children 0.131
< 5 25 (83.2) 26 (86.7)
> 5 5 (16.8) 4 (13.3)
Breast feeding 0.945
No 2 (6.7) 2 (6.7)
Yes 28 (93.3) 28 (93.3)
Family history of cancer 0.128
No 18 (60.0) 24 (80.0)
Yes 12 (40.0) 6 (20.0)
*Pearson chi square test.
Law et al. Lipids in Health and Disease 2014, 13:139 Page 3 of 7
http://www.lipidworld.com/content/13/1/139Sixty women (88.2%) completed the entire assessment
process from the first cycle of chemotherapy to the sixth
cycle. Five women (7.3%) withdrew from the intervention
group because they were unable to take VCO, and three
(4.5%) women from the control group refused to partici-
pate in the study because they were not feeling well. The
final intervention group consisted of 30 women, and the
control group consisted of 30 women. Characteristics of
both the intervention and control groups are presented in
Table 1. The age of the intervention group ranged from
31–73 years (mean 47.10 years), and those in the control
group ranged in age from 30 to 64 years (mean 49.90 years).
The majority of the patients were Malay (intervention
group, 96.7%; control group, 80%) and had a secondary
level of education (intervention group, 53.3%; control
group, 36.7%). In the intervention group, 46.7% of partici-
pants were housewives, whereas in the control group
46.7% of participants were civil servants. Most participants
had an income ranging between RM 1000 and 3000.
Ninety percent of subjects in the intervention group were
married compared to 83.3% in the control group. In both
groups, 93.3% of patients breastfed their children. In the
intervention and control groups, 40% and 20% of subjects,
respectively, had a family history of cancer. Statisti-
cally, there were no significant differences between the
intervention and control groups in terms of their demo-
graphic data (Table 1).
Functioning and global QOL
Table 2 shows patients’ functioning and global QOL as
measured by the EORTC QLQ-C30. All aspects of func-
tioning showed improvement over time, and every func-
tioning item had higher values in the intervention group
compared to the control group at last chemotherapy
cycle. Significant differences in mean functioning and
global QOL scores between the intervention and control
groups were also detected. At the sixth cycle of chemo-
therapy for global QOL has shown a significant different
with a P value < 0.01 (t-stat: 3.325). It can be proven where
the difference of the mean score for global quality of life
at sixth chemotherapy cycle for the intervention group
was 72.03 (SD: 12.81) while the control group was 60.34
(SD: 20.36). These results show more improvement in the
intervention group than in the control group when com-
paring the mean score from the pre-assessment (first
cycle) to the post-assessment (sixth cycle).
Symptoms
For the symptoms measured using the EORTC QLQ-
C30, there were no significant differences in mean symp-
tom scores between the two groups at any cycle of the
assessment (Table 3). However, by comparing mean score
between the intervention group and the control group in
the pre-assessment time point for all symptoms, theintervention group has indicates of a higher mean
compared to the control group. Loss of appetite was the
most detrimental symptom affecting the QOL for both
Table 2 Breast cancer patients’ functioning and global quality of life scores as measured by the EORTC QLQ-C30*
(n = 60, 30 in each group)
Functioning 1st Chemotherapy
cycle mean score (SD)
3rd Chemotherapy
cycle mean score (SD)
4th Chemotherapy
cycle mean score (SD)
5th Chemotherapy
cycle mean score (SD)
6th Chemotherapy
cycle mean score (SD)
Intervention Control Intervention Control Intervention Control Intervention Control Intervention Control
Physical 69.69 73.57 68.72 68.72 70.53 75.18 78.12 74.48 83.00 75.18
(18.42) (27.11) (16.39) (18.81) (16.23) (15.00) (12.40) (19.28) (12.17) (15.93)
Role 58.05 67.35 60.77 59.19 60.76 67.25 69.21 64.96 77.98** 62.09**
(25.06) (35.99) (22.19) (30.41) (21.35) (20.16) (17.54) (19.07) (19.42) (22.67)
Emotional 60.77 60.77 62.93 64.36 66.09 66.12 71.23 65.81 76.09** 62.30**
(20.35) (29.78) (14.87) (26.72) (15.53) (21.12) (15.52) (19.59) (14.86) (20.92)
Cognitive 61.84 72.99 72.31 73.56 69.35 70.69 73.11 65.52 80.65** 64.37**
(25.12) (24.96) (18.64) (19.68) (19.28) (25.06) (13.38) (23.12) (15.56) (26.62)
Social 66.67 67.44 66.16 67.41 69.37 68.76 73.16 63.04 77.43 63.03
(27.90) (31.03) (22.93) (28.70) (23.21) (20.48) (19.99) (21.68) (20.43) (24.90)
Global 51.60** 65.79** 55.64** 71.54** 61.84 63.50 74.21 67.53 72.03** 60.34**
(13.86) (18.95) (17.40) (16.88) (15.19) (18.29) (54.86) (13.96) (12.82) (20.36)
*A higher value indicates a higher level of functioning and quality of life: min: 0, max: 100.
**Significant difference between intervention and control groups, P <0.01;
Independent t-test.
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group had a higher mean score for this symptom (50.53,
SD: 33.20) compared to the control group (33.35, SD:
30.88). In addition, fatigue, dyspnea, and sleep difficulties
were also lower at sixth cycle of chemotherapy as com-
pared to the first cycle assessment in the intervention
group. These results indicate that the QOL increased as
the mean score of symptoms decreased.
Breast-specific scores
The QOL scores for breast cancer patients measured by
the EORTC QLQ-BR23 are shown in Table 4. Except for
sexual enjoyment, improvements were seen in all other
functioning scores (i.e., body image, sexual function and
future perspective) compared to the first cycle of chemo-
therapy in the intervention group. The mean score for
sexual function improved in the intervention group be-
tween the first and the sixth cycle, but unfortunately, the
mean differences were not significant between groups
(P > 0.01; t-stat: −1.507). At the fifth chemotherapy cycle,
the intervention group had a higher mean score for sex-
ual function compared to the control group (53.83, SD:
27.58 vs. 38.54, SD: 34.04). For symptom status, none of
the symptoms (P > 0.01) has shown significant mean
score differences between groups at any cycles of the
chemotherapy. By comparing between the mean score
for intervention group of each symptoms, the symptom
of breast (15.59, SD: 17.58 vs 15.08, SD: 12.61) and sys-
tematic therapy side effects (38.80, SD: 19.99 vs 38.24,
SD: 18.83) has indicate lower mean score at the sixth
cycle prior to the first cycle. The side effects of systemictherapy in the control group had the highest mean score
of symptoms, which could diminish the QOL among
breast cancer patients. Although the score for upset by
hair loss was somewhat higher in the intervention group
than the control group after six cycles of chemotherapy,
the difference between the groups was not statistically
significant.
Discussion
This study was designed to evaluate the effectiveness of
VCO on the QOL of patients with breast cancer
throughout six cycles of chemotherapy. The results
showed that the functional status and global QOL were
improved in the intervention group, with significant
mean score differences between groups. Additionally,
symptoms of fatigue, dyspnea, sleep difficulties and loss
of appetite were also decreased in the intervention
group, measured at the sixth cycle of chemotherapy. For
breast-specific scores, there was improvement in all
other patients’ functioning scores likes body image, sex-
ual function and future perspective. Breast symptoms
and side effects of systemic therapy showed significant
mean score differences between groups at the sixth cycle
of chemotherapy.
The findings of this study showed that women had a
satisfactory score on functioning and global quality of
life after consumption of VCO. In fact, breast cancer
and its treatment, especially chemotherapy, can disrupt
the QOL of breast cancer patients [12,13,26]. In
addition, a study done by Vardy [15] & Lemieux et al.,
[27] reported that quality of life was most affected after
Table 3 Breast cancer patients’ symptoms scores as measured by the EORTC QLQ-C30* (n = 60, 30 in each group)
Symptom 1st Chemotherapy
cycle mean score (SD)
3rd Chemotherapy
cycle mean score (SD)
4th Chemotherapy
cycle mean score (SD)
5th Chemotherapy
cycle mean score (SD)
6th Chemotherapy
cycle mean score (SD)
Intervention Control Intervention Control Intervention Control Intervention Control Intervention Control
Fatigue 49.34 36.38 44.26 39.93 46.06 40.56 45.44 41.71 45.88 47.26
(22.75) (24.50) (11.69) (22.94) (13.77) (15.76) (15.29) (15.59) (16.10) (17.58)
Nausea and
vomiting
31.19 24.13 36.03 28.73 30.10 26.55 30.11 33.91 30.64 39.08
(25.38) (25.03) (24.02) (28.48) (18.95) (20.53) (20.82) (23.35) (21.98) (31.89)
Pain 34.03 28.16 34.97 29.87 37.09 29.30 34.40 64.35 34.94 41.95
(23.34) (26.39) (16.86) (21.07) (17.05) (21.66) (18.72) (148.92) (20.35) (20.72)
Dyspnoea 22.57 14.94 21.51 12.63 11.49 15.58 18.82 19.53 18.29 20.68
(26.37) (23.30) (25.17) (18.71) (18.72) (18.41) (23.88) (22.74) (25.61) (24.26)
Sleep difficulties 36.55 24.12 38.73 26.42 37.09 33.32 33.86 35.61 31.71 39.06
(26.33) (30.73) (24.50) (27.29) (22.67) (28.18) (22.16) (23.47) (25.23) (21.96)
Loss of appetite 50.53 33.35 49.47 44.25 48.91 43.68 41.38 43.66 40.85 44.82
(33.20) (30.88) (27.05) (31.60) (19.72) (25.38) (23.14) (23.76) (23.52) (32.47)
Constipation 31.16 28.75 37.64 25.28 38.16 24.14 38.70 34.47 40.86 41.38
(27.12) (35.34) (23.38) (27.69) (19.83) (28.05) (24.50) (30.20) (26.83) (31.71)
Diarrhoea 12.90 10.34 17.22 11.49 17.19 16.09 19.34 17.23 26.86 20.69
(20.50) (20.13) (22.57) (20.46) (20.84) (22.92) (22.39) (22.92) (59.83) (27.34)
Financial difficulties 32.25 26.43 25.81 28.73 33.33 27.58 36.56 31.02 37.62 34.48
(31.61) (30.06) (25.40) (31.78) (31.04) (30.95) (29.01) (29.46) (29.50) (31.48)
*A higher value indicates a higher level of functioning and quality of life: min: 0, max: 100.
**Significant different significant difference between intervention and control groups, P < 0.01;
Independent t-test.
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treatments. At the sixth chemotherapy cycle, mean score
for global QOL for the intervention group was 72.03
(SD: 12.82) while the control group was only 60.34 (SD:
20.36). This finding is contrary to the study performed
by Montazeri et al., [28], whereby the global health score
was reduced. Nevertheless, the results are similar to
Costanzo et al., [29], which showed improvement in
physical functioning. It is believed that consumption of
VCO helped in increasing the energy level as well as
maintaining physical function among the breast cancer
patients. The effects of VCO in terms of energy, fats and
protein metabolism have been demonstrated in the study
carried out by Soerjodibroto [22]. The study highlighted
that VCO had a positive effect on immune responses
among HIV positive patients which showed improve-
ments and maintained stable throughout the study. Lau-
ric acid which is a disease- fighting substance that has
many health benefits [30-32], is abundant in coconut oil.
Fife [33] also mentioned that coconut oil improves nu-
trient absorption, boosts energy, possesses potent anti-
microbial properties, and improves energy metabolism
in the brain. There have been emerging fundamental evi-
dences to explain the positive clinical effects of VCO on
human health.For the symptom scores evaluated in this study, no
significant differences between the two groups were de-
tected. Thus, the improvement of the symptoms scores
were presented such as fatigue, dyspnea, sleep difficulties
and loss of appetite at the sixth chemotherapy cycle. Ser-
ious side effects of chemotherapy often are perceived by
patients as distress factors that contribute to poor QOL
[12,26]. For example, the most commonly reported symp-
tom that affects QOL was loss of appetite. During the pre-
assessment, the intervention group had a higher mean
score for this symptom (50.53, SD: 33.20) than the control
group (33.35, SD: 30.88). However, after VCO supplemen-
tation, the mean score of the intervention group declined
and no significant difference between the two groups was
detected. Coconut oil is unique, known as medium-chain
triglycerides that are usually used to improve patients’ nu-
tritional status [32,33]. In addition, maintaining a good
appetite can promote wound healing and encourage a
speedy recovery from illness [7].
The QOL scores of breast cancer patients as measured
by the EORTC QLQ-BR23 in this study showed improve-
ment in several measures of function such as body image,
future perspective and sexual function in the intervention
group. Compared to a study performed by Montazeri
et al., [34], instead use found that most of the function
Table 4 Breast cancer patients’ functioning and symptoms scores as measured by the EORTC QLQBR23 (n = 60, 30 in
each group)
1st Chemotherapy
cycle mean score (SD)
3rd Chemotherapy
cycle mean score (SD)
4th Chemotherapy
cycle mean score (SD)
5th Chemotherapy
cycle mean score (SD)
6th Chemotherapy
cycle mean score (SD)
Intervention Control Intervention Control Intervention Control Intervention Control Intervention Control
Functioning*
Body image 64.52 73.93 67.75 68.70 67.18 75.02 72.66 71.75 75.59 68.72
(21.71) (23.25) (18.24) (24.24) (19.87) (17.71) (21.16) (18.23) (24.81) (18.91)
Sexual functioning 46.82 33.83 47.37 32.16 54.90 39.09 53.83 38.54 53.85 42.55
(31.23) (35.49) (30.26) (28.93) (28.97) (31.96) (27.58) (34.04) (28.85) (34.17)
Sexual enjoyment 34.43 27.59 25.85 19.55 19.33 24.14 22.60 25.28 20.44 27.59
(32.86) (37.91) (29.58) (30.31) (25.55) (30.81) (29.14) (30.49) (28.21) (31.04)
Future perspective 31.08 48.28 37.53 48.31 37.58 48.35 50.60 50.69 53.90 56.48
(24.30) (36.37) (25.54) (35.27) (22.49) (29.14) (25.80) (29.18) (22.42) (25.51)
Symptom+
Arm 24.72 17.99 25.43 19.53 27.23 24.51 27.94 22.97 27.94 24.88
(22.72) (18.39) (17.73) (21.13) (20.86) (22.29) (17.42) (16.51) (18.35) (17.97)
Breast 15.59 12.55 10.74 14.88 10.21 18.10 13.71 16.37 15.04 20.68
(17.58) (18.71) (11.82) (19.08) (8.26) (18.38) (9.76) (12.09) (12.61) (16.75)
Systematic therapy
side effect
38.80 33.18 39.02 37.29 39.79 39.91 42.10 41.20 38.24 48.65
(19.99) (16.77) (14.73) (16.87) (13.99) (19.25) (17.99) (19.68) (18.83) (18.23)
Upset by hair loss 25.28 31.03 24.51 16.67 34.48 25.28 34.84 28.96 36.77 36.77
(30.13) (36.42) (24.73) (27.46) (31.48) (31.70) (24.45) (30.31) (28.82) (31.31)
*Scores range from 0 to 100, with higher scores representing a higher level of functioning.
+Scores range from 0 to 100, with higher scores representing a higher level of symptoms.
**Significant different, P <0.01;
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of premature menopause following adjuvant systemic
therapy in breast cancer patients. Physical and emotional
status have been shown to affect sexuality, including nega-
tive body image, feelings of sexual unattractiveness, loss of
femininity, depression, and anxiety following breast cancer
diagnosis [35]. Ganz et al., [36] found that sexual function-
ing was worse for women who received chemotherapy. A
similar result has been noted in another study from University
of Sto. Tomas unveiled the beneficial effects of VCO on
health and sex life. 13% of the VCO takers (189 partici-
pants) experienced becoming sexually active in the whole
duration of their participation in the VCO study [37].
The current study was limited by the small number of
breast cancer patients in Kelantan, Malaysia. Therefore,
a large, multi-state comparison with varying demograph-
ics should be conducted in Malaysia. Furthermore, add-
itional VCO intervention studies should be performed to
confirm the specific beneficial effects of VCO that were
detected in this study.
Conclusion
This study revealed improved functional and global QOL
of breast cancer patients who consumed VCO during the
six cycle chemotherapy treatment and showed significantdifferences in functional and global QOL between the inter-
vention and control groups. VCO may help in promoting
the functional and global QOL of breast cancer patients
who are undergoing chemotherapy. These results also sug-
gest that VCO consumption could reduce the women’s
symptoms and improve several items of functional status
such as body image, future perspective and sexual function.
Based on the results, there are certainly good prospect of
utilizing VCO as supplementation among breast cancer
patients towards achieving a positive QOL.
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